Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.44 |
| ▸ | CALML3 | P27482 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SDHA | P31040 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833603 | 0.85 | MAOA (0.42) | MAOACALML3MAOBF10 | |
| SCHEMBL6925097 | 0.82 | CALML3 (0.58) | MAOACALML3MAOB | |
| SCHEMBL5625330 | 0.82 | CALML3 (0.58) | MAOACALML3MAOB | |
| SCHEMBL5236580 | 0.82 | CALML3 (0.58) | MAOACALML3MAOB | |
| SCHEMBL6827066 | 0.82 | MAOA (0.64) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6827071 | 0.82 | MAOA (0.64) | MAOACALML3MAOBLMNAPTGS1 | |
| Trifluoroacetic Acid SCHEMBL5623895 | 0.81 | CALML3 (0.54) | MAOACALML3MAOB | |
| SCHEMBL5623899 | 0.80 | CALML3 (0.44) | MAOACALML3MAOB | |
| SCHEMBL7256130 | 0.80 | CALML3 (0.47) | MAOACALML3F10 | |
| SCHEMBL4016280 | 0.80 | CALML3 (0.47) | MAOACALML3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
| US-6365751-B1 | ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC | ZENECA LTD. (GB) | 2002-04-02 | — | — | US | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | MAOA 2791/4885CALML3 4763/4885MAOB 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.